OMEROS CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $238.1M

Website: http://www.omeros.com/

Clinical Trials

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Phase 2

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: OMS906 study drug

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-07

Lead Sponsor: Omeros Corporation

Target Recruit Count: 25

Registration Number: NCT06298955

Locations: 🇬🇧
Omeros Investigational Site, Leeds, United Kingdom

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Phase 2

Recruiting

Conditions: C3 Glomerulopathy
Idiopathic Immune Complex-Mediated Glomerulonephritis

Interventions: Drug: OMS906 study drug

First Posted Date: 2024-01-17

Last Posted Date: 2024-04-18

Lead Sponsor: Omeros Corporation

Target Recruit Count: 20

Registration Number: NCT06209736

Locations: 🇬🇧
Omeros Investigational Site, Newcastle Upon Tyne, United Kingdom

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Phase 2

Active, not recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: OMS906 Study Drug - 3 mg/kg
Drug: OMS906 Study Drug - 5 mg/kg
Drug: Ravulizumab

First Posted Date: 2023-08-02

Last Posted Date: 2025-01-08

Lead Sponsor: Omeros Corporation

Target Recruit Count: 12

Registration Number: NCT05972967

Locations: 🇬🇧
Omeros Investigational Site, Leeds, United Kingdom

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase 1

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: OMS906 study drug

First Posted Date: 2023-06-05

Last Posted Date: 2023-06-05

Lead Sponsor: Omeros Corporation

Target Recruit Count: 10

Registration Number: NCT05889299

Locations: 🇺🇦
Omeros Investigational Site, Kyiv, Ukraine

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Phase 2

Recruiting

Conditions: Thrombotic Microangiopathies
Hematopoietic Stem Cell Transplantation

First Posted Date: 2023-05-11

Last Posted Date: 2023-11-18

Lead Sponsor: Omeros Corporation

Target Recruit Count: 18

Registration Number: NCT05855083

Locations: 🇪🇸
Omeros Investigational Site, Pamplona, Spain

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Conditions: Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

First Posted Date: 2020-01-30

Last Posted Date: 2024-08-06

Lead Sponsor: Omeros Corporation

Registration Number: NCT04247906

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Phase 3

Terminated

Conditions: IgA Nephropathy

Interventions: Biological: OMS721
Other: Vehicle (D5W or saline)

First Posted Date: 2018-07-31

Last Posted Date: 2024-03-15

Lead Sponsor: Omeros Corporation

Target Recruit Count: 356

Registration Number: NCT03608033

Locations: 🇬🇧
Omeros Investigational Site, London, United Kingdom
🇺🇸
Omeros Investigation Sites, Phoenix, Arizona, United States

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

Phase 3

Recruiting

Conditions: Thrombotic Microangiopathies
Atypical Hemolytic Uremic Syndrome

Interventions: Biological: OMS721

First Posted Date: 2017-07-02

Last Posted Date: 2018-10-18

Lead Sponsor: Omeros Corporation

Target Recruit Count: 80

Registration Number: NCT03205995

Locations: 🇺🇸
Omeros Investigational Site, Chicago, Illinois, United States

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Phase 2

Conditions: IgAN
Lupus Nephritis
C3 Glomerulopathy
MN

Interventions: Biological: OMS721 (narsoplimab)

First Posted Date: 2016-02-15

Last Posted Date: 2020-04-10

Lead Sponsor: Omeros Corporation

Target Recruit Count: 54

Registration Number: NCT02682407

Locations: 🇭🇰
Omeros Investigational Site, Sha Tin, Hong Kong

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Phase 2

Completed

Conditions: Thrombotic Microangiopathies

Interventions: Biological: OMS721

First Posted Date: 2014-08-21

Last Posted Date: 2024-08-28

Lead Sponsor: Omeros Corporation

Target Recruit Count: 58

Registration Number: NCT02222545

Locations: 🇹🇭
Omeros Investigational Site, Pathum Thani, Thailand

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy